

similar altered markers (although with different magnitude effect) in schizophrenia and schizotypy.

SP01. Human rights and psychiatric treatment: a round table of concerned partners

Chair: P. Cosyns (B)

Participants:

Jean Claus, Council of Europe (F)

Jean Canneva, UNAFAM (F)

Paul Cosyns, AEP (B)

Nina Rehnqvist, National Board of Health and Welfare (S)

PL03. Plenary Nobel Laureate Lecture: Molecular biology of memory and its disorders

Introduction by: Sten Grillner (S)

PL03

Molecular biology of memory and its disorders

E.R. Kandel*. *Columbia University College of Physicians & Surgeons, Senior Investigator, Howard Hughes Medical Institute, USA*

I will consider the molecular mechanisms whereby a transient short-term memory is converted into a stable, self-maintained, long-term memory. I will first outline studies in *Aplysia* and mice that show this conversion from short to long-term memory requires protein synthesis and this protein synthesis is reflected, on the cellular level, in the activation of a cascade of genes, that leads to the growth of new synaptic connections. Second, I will go on to consider mouse models of clinical defects in converting short to long-term hippocampal based memory, in particular age-related memory loss and Down's syndrome.

LS05. Health economics and schizophrenia (Sponsored by Eli Lilly, Sweden)

Chair: N. Sartorius (CH)

LS05.1

Introduction to health economics: terminology and concepts – types of economic evaluations. Choice perspective. Cost components. Markov models

L. Jönssen. *Sweden*

No abstract was available at the time of printing.

LS05.2

Ethical aspects – who should have the right to treatment

S. Thelander. *Sweden*

No abstract was available at the time of printing.

LS05.3

Health economic evaluations in schizophrenia

M. Knapp. *UK*

No abstract was available at the time of printing.

LS06. Insights, promise, and renewed hope in the treatment of schizophrenia (Sponsored by Bristol-Myers Squibb)

Chairs: L. Farde (S), M. Bourin (F)

LS06.1

Welcome and introduction

L. Farde. *Sweden*

No abstract was available at the time of printing.

LS06.2

Schizophrenia: a chronic illness seeking a long-term solution

R.S. Kahn. *The Netherlands*

No abstract was available at the time of printing.

LS06.3

Stabilizing the dopamine-serotonin system: a new goal in the management of schizophrenia

L. Farde. *Sweden*

No abstract was available at the time of printing.

LS06.4

Antipsychotic effect and clinical benefit in the management of schizophrenia

M. Bourin. *France*

No abstract was available at the time of printing.

LS06.5

Safety, tolerability and compliance in the use of antipsychotics

W.W. Fleischhacker. *Austria*

No abstract was available at the time of printing.